197 related articles for article (PubMed ID: 37115930)
1. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
[TBL] [Abstract][Full Text] [Related]
2. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding.
Li S; Chen K; Zhang Y; Barnes SD; Jaichander P; Zheng Y; Hassan M; Malladi VS; Skapek SX; Xu L; Bassel-Duby R; Olson EN; Liu N
Genes Dev; 2019 Jun; 33(11-12):626-640. PubMed ID: 30975722
[TBL] [Abstract][Full Text] [Related]
3. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
[TBL] [Abstract][Full Text] [Related]
4. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
[TBL] [Abstract][Full Text] [Related]
5. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
6. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
7. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
[TBL] [Abstract][Full Text] [Related]
8. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway.
Hernandez KC; Shah AM; Lopez VA; Tagliabracci VS; Chen K; Xu L; Bassel-Duby R; Olson EN; Liu N
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2315925121. PubMed ID: 38227654
[TBL] [Abstract][Full Text] [Related]
9. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.
Hsu JY; Danis EP; Nance S; O'Brien JH; Gustafson AL; Wessells VM; Goodspeed AE; Talbot JC; Amacher SL; Jedlicka P; Black JC; Costello JC; Durbin AD; Artinger KB; Ford HL
Cell Rep; 2022 Feb; 38(5):110323. PubMed ID: 35108532
[TBL] [Abstract][Full Text] [Related]
10. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
[TBL] [Abstract][Full Text] [Related]
11. Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.
Zhang M; Zhu B; Davie J
J Biol Chem; 2015 Jan; 290(1):310-24. PubMed ID: 25404735
[TBL] [Abstract][Full Text] [Related]
12. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
[TBL] [Abstract][Full Text] [Related]
13. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.
Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C
Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344
[TBL] [Abstract][Full Text] [Related]
14. Actin-related protein 5 functions as a novel modulator of MyoD and MyoG in skeletal muscle and in rhabdomyosarcoma.
Morita T; Hayashi K
Elife; 2022 Mar; 11():. PubMed ID: 35348112
[TBL] [Abstract][Full Text] [Related]
15. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of transforming growth factor-beta-mediated inhibition of growth arrest and differentiation in a myoblast cell line.
Murakami M; Ohkuma M; Nakamura M
Dev Growth Differ; 2008 Feb; 50(2):121-30. PubMed ID: 18211587
[TBL] [Abstract][Full Text] [Related]
17. Selective Targeting of Myoblast Fusogenic Signaling and Differentiation-Arrest Antagonizes Rhabdomyosarcoma Cells.
Granados VA; Avirneni-Vadlamudi U; Dalal P; Scarborough SR; Galindo KA; Mahajan P; Galindo RL
Cancer Res; 2019 Sep; 79(18):4585-4591. PubMed ID: 31331911
[TBL] [Abstract][Full Text] [Related]
18. Sequential recruitment of PCAF and BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13-acetate-induced early differentiation of rhabdomyosarcoma-derived cells.
Li ZY; Yang J; Gao X; Lu JY; Zhang Y; Wang K; Cheng MB; Wu NH; Zhang Y; Wu Z; Shen YF
J Biol Chem; 2007 Jun; 282(26):18872-8. PubMed ID: 17468105
[TBL] [Abstract][Full Text] [Related]
19. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
